Tokuhira M, Kimura Y, Tabayashi T, Watanabe N, Tsuchiya S, Takaku T, Iriyama N, Sato E, Nakazato T, Mitsumori T, Ishikawa M, Fujita H, Kizaki M, Ando M, Hatta Y, Iwanaga E, Kawaguchi T.

Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects.

Tokuhira M, Kimura Y, Tabayashi T, Watanabe N, Tsuchiya S, Takaku T, Iriyama N, Sato E, Nakazato T, Mitsumori T, Ishikawa M, Fujita H, Kizaki M, Ando M, Hatta Y, Iwanaga E, Kawaguchi T.

Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects.

Int J Hematol 118(2):210-220.doi: 10.1007/s12185-023-03606-x.

https://pubmed.ncbi.nlm.nih.gov/37129800/

Furuta Y, Gushima R, Naoe H, Honda M, Tsuruta Y, Nagaoka K, Watanabe T, Tateyama M, Fujimoto N, Hirata S, Miyagawa E, Sakata K, Mizuhashi Y, Iwakura M, Murai M, Matsuoka M, Komohara Y, Tanaka Y.

Possible Association of Mutations in the MEFV Gene with the Intestinal Phenotype of Behcet’s Disease and Refractoriness to Treatment.

Kidoh M, Oda S, Takashio S, Kawano Y, Hayashi H, Emoto T, Shigematsu S, Yoshimura F, Nakaura T, Nagayama Y, Matsuoka M, Ueda M, Tsujita K, Hirai T.

Cardiac MRI-derived Extracellular Volume Fraction versus Myocardium-to-Lumen R1 Ratio on Post-contrast T1 Mapping for Detecting Cardiac Amyloidosis.

Morishima T, Takahashi K, Chin DWL, Wang Y, Tokunaga K, Arima Y, Matsuoka M, Suda T, Takizawa H.

Phospholipid metabolic adaptation promotes survival of IDH2 mutant acute myeloid leukemia cells.

Hiramatsu H, Nosaka K, Kusumoto S, Nakano N, Choi I, Yoshimitsu M, Imaizumi Y, Hidaka M, Sasaki H, Makiyama J, Ohtsuka E, Jo T, Ogata M, Ito A, Yonekura K, Tatetsu H, Kato T, Kawakita T, Suehiro Y, Ishitsuka K, Iida S, Matsutani T, Nishikawa H, Utsunomiya A, Ueda R, Ishida T.

Landscape of immunoglobulin heavy chain γ gene class switch recombination in patients with adult T-cell leukemia-lymphoma.

Hiramatsu H, Nosaka K, Kusumoto S, Nakano N, Choi I, Yoshimitsu M, Imaizumi Y, Hidaka M, Sasaki H, Makiyama J, Ohtsuka E, Jo T, Ogata M, Ito A, Yonekura K, Tatetsu H, Kato T, Kawakita T, Suehiro Y, Ishitsuka K, Iida S, Matsutani T, Nishikawa H, Utsunomiya A, Ueda R, Ishida T.

Landscape of immunoglobulin heavy chain γ gene class switch recombination in patients with adult T-cell leukemia-lymphoma.

Haematologica 1;108(4):1173-1178.doi: 10.3324/haematol.2022.281435.

https://pubmed.ncbi.nlm.nih.gov/36420800/

Furuta R, Tatetsu H, Yasunaga JI, Ueno M, Oshiro K, Kumanomido S, Kawano Y, Higuchi Y, Honda Y, Mikami Y, Nosaka K, Matsuoka M.

Waldenstrom’s macroglobulinemia-like B cell lymphoma with MYD88 L265P mutation and t(14;18)(q32;q21) involving IGH-MALT1.

Tsuchiya S, Takaku T, Watanabe N, Iriyama N, Kimura Y, Iwanaga E, Sugimoto KJ, Mitsumori T, Ishikawa M, Nakazato T, Fujita H, Sato E, Hatta Y, Asou N, Kizaki M, Tokuhira M, Ando M, Kawaguchi T.

Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice.

Sakurada-Aono M, Sakamoto T, Kobayashi M, Takiuchi Y, Iwai F, Tada K, Sasanuma H, Hirabayashi S, Murakawa Y, Shirakawa K, Sakamoto C, Shindo K, Yasunaga JI, Matsuoka M, Pommier Y, Takeda S, Takaori-Kondo A.

HTLV-1 bZIP factor impairs DNA mismatch repair system.

Biochem Biophys Res Commun 21:657:43-49,2023. doi: 10.1016/j.bbrc.2023.03.049.

https://pubmed.ncbi.nlm.nih.gov/36972660/

Sakurada-Aono M, Sakamoto T, Kobayashi M, Takiuchi Y, Iwai F, Tada K, Sasanuma H, Hirabayashi S, Murakawa Y, Shirakawa K, Sakamoto C, Shindo K, Yasunaga JI, Matsuoka M, Pommier Y, Takeda S, Takaori-Kondo A.

HTLV-1 bZIP factor impairs DNA mismatch repair system.

Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T, Rai S, Katsuya H, Ishikawa J, Yamada H, Kato K, Tachibana M, Kakurai Y, Adachi N, Tobinai K, Yonekura K, Ishitsuka K.

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.

Kameda T, Kataoka K, Kamiunten A, Hidaka M, Miyoshi H, Nakano N, Nosaka K, Yoshimitsu M, Yasunaga JI, Kogure Y, Shide K, Miyahara M, Sakamoto T, Akizuki K, Hidaka T, Kubuki Y, Koya J, Kawano N, Yamashita K, Kawano H, Toyama T, Maeda K, Marutsuka K, Imaizumi Y, Kato K, Sugio T, Tokunaga M, Tashiro Y, Takaori-Kondo A, Miyazaki Y, Akashi K, Ishitsuka K, Matsuoka M, Ohshima K, Watanabe T, Kitanaka A, Utsunomiya A, Ogawa S, Shimoda K.

Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma.

Haematologica 1;108(8):2178-2191,2023. doi:10.3324/haematol.2022.281510.

https://pubmed.ncbi.nlm.nih.gov/36794502/

Kameda T, Kataoka K, Kamiunten A, Hidaka M, Miyoshi H, Nakano N, Nosaka K, Yoshimitsu M, Yasunaga JI, Kogure Y, Shide K, Miyahara M, Sakamoto T, Akizuki K, Hidaka T, Kubuki Y, Koya J, Kawano N, Yamashita K, Kawano H, Toyama T, Maeda K, Marutsuka K, Imaizumi Y, Kato K, Sugio T, Tokunaga M, Tashiro Y, Takaori-Kondo A, Miyazaki Y, Akashi K, Ishitsuka K, Matsuoka M, Ohshima K, Watanabe T, Kitanaka A, Utsunomiya A, Ogawa S, Shimoda K.

Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma.

Guo M, Chan HMT, Zhou QL, An O, Li Y, Song Y, Tan ZH, Ng HEV, Peramangalam PS, Tan ZQ, Cao X, Iwanaga E, Matsuoka M, Ooi MG, Jen WY, Koh LP, Chan E, Tan LK, Goh Y, Wang W, Koh BTH, Chan MC, Fullwood MJ, Chng WJ, Osato M, Pulikkan JA, Yang H, Chen L, Tenen DG.

Core binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis.

Blood 22;141(25):3078-3090.doi: 10.1182/blood.2022015830.

https://pubmed.ncbi.nlm.nih.gov/36796022/

Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, Amano M, Ishida T, Uike N, Utsunomiya A, Ohshima K, Tanaka J, Tokura Y, Tobinai K, Watanabe T, Uchimaru K, Tsukasaki K.

Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study.

Int J Hematol 117(2):206-215.doi: 10.1007/s12185-022-03473-y.

https://pubmed.ncbi.nlm.nih.gov/36308678/

Matsumoto K, Kuwata T, Tolbert WD, Richard J, Ding S, Prévost J, Takahama S, Judicate GP, Ueno T, Nakata H, Kobayakawa T, Tsuji K, Tamamura H, Smith AB 3rd, Pazgier M, Finzi A, Matsushita S.

Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical Isolates.

Yasunaga JI.

Viral, genetic, and immune factors in the oncogenesis of adult T-cell leukemia/lymphoma.

Int J Hematol 117(4):504-511,2023.doi: 10.1007/s12185-023-03547-5.

https://pubmed.ncbi.nlm.nih.gov/36705848/

Yasunaga JI.

Viral, genetic, and immune factors in the oncogenesis of adult T-cell leukemia/lymphoma.

Fukuta T, Tanaka T, Hashimoto T, Isahaya K, Kubo Y, Yamano Y, Satomi K, Hiraoka N, Shirakawa N, Arakawa A, Ogawa C, Nishimura N, Aoki J, Ito A, Inamoto Y, Kim SW, Fukuda T.

Nelarabine-induced myelopathy in patients undergoing allogeneic hematopoietic cell transplantation: a report of three cases.

Int J Hematol 117(6):933-940,2023.doi: 10.1007/s12185-023-03539-5.

https://pubmed.ncbi.nlm.nih.gov/36705847/

Mizuhashi Y, Hirata S, Sakata K, Miyagawa E, Iwakura M, Murai M, Sasai T, Matsuoka M.

Overlap syndrome involving anti-OJ antibody-positive polymyositis, systemic lupus erythematosus and Sjögren’s syndrome: A case report and literature review.

Konishi T, Ogawa H, Najima Y, Hashimoto S, Kito S, Atsuta Y, Wada A, Adachi H, Konuma R, Kishida Y, Nagata A, Yamada Y, Kaito S, Mukae J, Marumo A, Noguchi Y, Shingai N, Toya T, Igarashi A, Shimizu H, Kobayashi T, Ohashi K, Doki N, Murofushi KN.

Outcomes of allogeneic haematopoietic stem cell transplantation with intensity-modulated total body irradiation by helical tomotherapy: a 2-year prospective follow-up study.

Ishida T, Ito S, Tanaka J, Uchiyama M, Kawano Y, Moreau P, Martin T, Risse ML, Tada K, Suzuki K, Ishizawa K.

Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomised, open label, phase 3 IKEMA study.

Jpn J Clin Oncol 52(12):1446-1449,2022.doi: 10.1093/jjco/hyac137.

https://pubmed.ncbi.nlm.nih.gov/36073950/

Nishiyama-Fujita Y, Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto K, Fujita H, Fujioka I, Tsuchiya S, Kimura Y, Iwanaga E, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T.

Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors.

Ann Med 54(1):1244-1254.doi: 10.1080/07853890.2022.2069280.

https://pubmed.ncbi.nlm.nih.gov/35486442/